Glaucoma drug which is b-1 selectve p-blocker is ?
**Core Concept**
Glaucoma is a group of eye conditions that damage the optic nerve, often due to abnormally high pressure in the eye. Topical medications are commonly used to lower intraocular pressure (IOP) and slow disease progression. Beta-blockers, a class of medications, are among the first-line treatments for glaucoma. These drugs work by decreasing the production of aqueous humor, thereby reducing IOP.
**Why the Correct Answer is Right**
Betaxolol is a selective β-1 adrenergic receptor blocker, which means it preferentially targets the β-1 receptors in the eye, reducing the production of aqueous humor without causing significant systemic side effects. This selectivity is crucial in minimizing the risk of systemic β-2 receptor blockade, which can lead to bronchospasm, a particular concern in patients with asthma or chronic obstructive pulmonary disease (COPD). Betaxolol's β-1 selectivity allows for effective IOP reduction while minimizing the risk of systemic adverse effects.
**Why Each Wrong Option is Incorrect**
**Option A:** Timolol is a non-selective β-blocker, which means it blocks both β-1 and β-2 receptors. This can lead to systemic side effects, including bronchospasm, and is less desirable than a β-1 selective agent like betaxolol.
**Option B:** Levobunolol is a non-selective β-blocker similar to timolol. It is effective in reducing IOP but carries a higher risk of systemic side effects due to its lack of β-1 selectivity.
**Option C:** Carteolol is a non-selective β-blocker with intrinsic sympathomimetic activity (ISA). While it has a unique mechanism of action, it is not a β-1 selective agent like betaxolol.
**Clinical Pearl / High-Yield Fact**
When choosing a topical glaucoma medication, remember that β-1 selective agents like betaxolol are generally preferred over non-selective β-blockers due to their reduced risk of systemic side effects. This is particularly important in patients with respiratory conditions like asthma or COPD.
**✓ Correct Answer: D. Betaxolol**